Search

Your search keyword '"Sbidian, E."' showing total 4 results
Start Over Author "Sbidian, E." Database OpenAIRE
4 results on '"Sbidian, E."'

1. Concordance of severity scores assessed on photographs in Hidradenitis suppurativa

Author

Prouteau, C, Dinulescu, M, oger, E, Pruvost-Balland, C, Buche, S, Cogrel, O, Delage, M, Maruani, A, Nicol, I, Sbidian, E, Villani, A P, Viguier, M, Chastagner, M, Grodner, C, Kaoutar, J, Laurent, C, Leducq, S, Dupuy, A, Droitcourt, C, CHU Pontchaillou [Rennes], Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Bordeaux [Bordeaux], Institut Pasteur [Paris] (IP), Centre Médical de l'Institut Pasteur (CMIP), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Marseille, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor [Créteil], Centre d'Investigation Clinique Henri Mondor (CIC Henri Mondor), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Reims (CHU Reims), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut Pasteur [Paris], Centre Médical de l'Institut Pasteur, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, CHU Henri Mondor, and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Hidradenitis suppurativa, Standardized photographs, [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS, Photographic assessments
Abstract

International audience

Published
2020

2. Early major adverse cardiovascular events following the initiation of the anti-interleukin 12/23 antibody ustekinumab. A population-based case-time-control study

Author

Poizeau, F., Nowak, E., Kerbrat, S., Droitcourt, C., Sbidian, E., Guillot, B., Bachelez, H., Ait-Oufella, H., Oger, E., Dupuy, A., Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Lapeyronie [Montpellier] (CHU), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), and Jonchère, Laurent

Subjects
[SDV] Life Sciences [q-bio], Monoclonal antibody, Major adverse cardiovascular events (MACE), [SDV]Life Sciences [q-bio], Ustekinumab, cardiovascular diseases, Cardiovascular risk
Abstract

International audience; Ustekinumab, a monoclonal antibody that targets interleukin (IL)-12/23, is used to treat psoriasis, psoriatic arthritis and Crohn disease. In 2011, a meta-analysis of randomized trials alerted on a potential risk of major adverse cardiovascular events (MACE) within the first months after the initiation of anti-IL-12/23 antibodies. Our objective was to assess if ustekinumab initiation may trigger MACE. Using the French National Health Insurance database, covering 66 million subjects, we included all patients exposed to ustekinumab between 2010 and 2016, classified according to their cardiovascular risk level (high vs. low risk). We conducted a case-time-control study. We defined the ‘risk’ period as the 6 months before MACE, defined as myocardial infarctions and strokes, and the ‘reference’ period as the 6 months before the risk period. The initiation of ustekinumab was screened in both periods, enabling to assess the odds-ratio (OR) between the initiation of ustekinumab and MACE. Among the 9290 patients exposed to ustekinumab, 179 displayed MACE: 65 myocardial infarctions, 68 unstable anginas and 46 strokes. Among patients at high-level cardiovascular risk, a significant association between ustekinumab initiation and MACE occurrence was identified (OR, 4.17; 95% CI, 1.19-14.59). Conversely, no association was found in patients at low-level cardiovascular risk (OR, 0.30; 95% CI, 0.03-3.13). From real-world data, we suggest that ustekinumab initiation could trigger MACE in patients at high cardiovascular risk, in line with current immunologic models of atherosclerotic disease. These results should call for caution regarding the prescription of ustekinumab in patients at high cardiovascular risk.

Published
2019

3. [Acitretin]

Author

Sbidian, E., Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), and Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Keratolytic Agents, 030220 oncology & carcinogenesis, [SDV]Life Sciences [q-bio], Contraindications, Drug, Humans, Psoriasis, Dermatology, Acitretin
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results